Nefesoglu F Z, Ayanoglu-Dülger G, Ulusoy N B, Imeryüz N
School of Pharmacy, Department of Pharmacology, Marmara University, Istanbul, Turkey.
Int J Clin Pharmacol Ther. 1998 Oct;36(10):549-53.
Enteric-coated tablets are designed to resist gastric fluids and to disrupt and dissolve in the alkaline medium of the small intestine. Main objective of the present study was to investigate whether the increase in gastric pH due to omeprazole treatment alters the release rate of a drug from enteric-coated formulation. To this end, we have compared the single dose pharmacokinetics of a single-unit enteric-coated salicylate to that of uncoated acetylsalicylic acid tablets in the presence and absence of omeprazole treatment.
Study was carried out according to 4 x 4 Latin square design. Eight healthy subjects received either uncoated acetylsalicylic acid tablets or single-unit enteric-coated sodium salicylate tablets alone or following 4 days of treatment with single-dose 20 mg omeprazole, and blood samples were collected for 24 hours. Serum salicylate levels were determined by the modified spectrophotometric method of Brodie et al. [1994].
Salicylate was absorbed rapidly from uncoated tablets but absorption of salicylate from enteric-coated tablets was delayed, as expected. According to our results, omeprazole treatment did not influence the bioavailability from uncoated acetylsalicylic acid tablets but the absorption rate of salicylate from enteric-coated tablets was increased significantly.
Findings of the present study demonstrate that omeprazole treatment significantly increases the rate of absorption of single-unit enteric-coated medication. Enhanced rate of absorption is most probably due to an early disruption of enteric coating and the intragastric release of the drug secondary to an omeprazole-mediated increase in gastric pH. The results of the present study also corroborate previous findings which have demonstrated highly variable absorption of enteric-coated single units.
肠溶片旨在抵抗胃液,并在小肠的碱性介质中崩解和溶解。本研究的主要目的是调查奥美拉唑治疗引起的胃内pH值升高是否会改变肠溶制剂中药物的释放速率。为此,我们比较了在有或没有奥美拉唑治疗的情况下,单剂量单单位肠溶水杨酸盐与未包衣乙酰水杨酸片的药代动力学。
研究按照4×4拉丁方设计进行。8名健康受试者分别单独服用未包衣的乙酰水杨酸片或单单位肠溶水杨酸钠片,或在单剂量20mg奥美拉唑治疗4天后服用,采集血样24小时。血清水杨酸盐水平采用Brodie等人[1994年]改良的分光光度法测定。
如预期的那样,水杨酸盐从未包衣片剂中迅速吸收,但从肠溶片剂中的吸收延迟。根据我们的结果,奥美拉唑治疗不影响未包衣乙酰水杨酸片的生物利用度,但肠溶片剂中水杨酸盐的吸收速率显著增加。
本研究结果表明,奥美拉唑治疗可显著提高单单位肠溶制剂的吸收速率。吸收速率的提高很可能是由于肠溶衣的早期破坏以及奥美拉唑介导的胃内pH值升高导致药物在胃内释放。本研究结果也证实了先前的研究结果,即肠溶单单位制剂的吸收高度可变。